TITLE

Efficacy of Eculizumab in a Patient with Paroxysmal Nocturnal Hemoglobinuria Requiring Transfusions 14 Years after a Diagnosis in Childhood

AUTHOR(S)
Ueda, Takahiro; Hayakawa, Jun; Yamanishi, Miho; Maeda, Miho; Fukunaga, Yoshitaka
PUB. DATE
April 2013
SOURCE
Journal of Nippon Medical School;2013, Vol. 80 Issue 2, p155
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal disorder characterized by chronic complement-mediated hemolysis. The humanized anti-C5 antibody eculizumab binds to the C5 protein and suppresses hemolysis by inhibiting C5b-9 generation. Here, we report on a 27-year-old woman who was found to have PNH in 1997 (at 13 years of age), without subsequent transfusions, thrombosis, or renal disorder. She had been experiencing frequent malaise and fatigue and was sometimes unable to participate in social activities. She had also experienced repeated hemolytic episodes due to infection, and the hemoglobin level had decreased from 7.0 to 5.0g/dL several times since February 2010. Red blood cell transfusion was necessary, and 6 months later, treatment with eculizumab was started. The hemoglobin level stabilized, and the patient became transfusion-independent. Furthermore, the patient showed significant improvements in fatigue scale scores and quality of life. Six months after the start of eculizumab therapy, the percentage of PNH-type red blood cells was found to have increased from 82.0% (1.95 x 1012 cells/L) to 89.1% (2.78 x 1012 cells/L). Furthermore, during treatment with eculizumab, intravascular hemolysis occurred due to a viral infection accompanied by a high fever. We also observed a persistent elevation in reticulocytes and total bilirubin levels, as well as a persistent reduction in haptoglobin levels. Extravascular hemolytic findings were also observed. Because treatment with eculizumab was started at a young age (27 years) and will be continued for many years, careful observation of the patient is required.
ACCESSION #
86991439

 

Related Articles

  • Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria. Hillmen, Peter; Hall, Claire; Marsh, Judith C.W.; Elebute, Modupe; Bombara, Michael P.; Petro, Beth E.; Cullen, Matthew J.; Richards, Stephen J.; Rollins, Scott A.; Mojcik, Christopher F.; Rother, Russell P. // New England Journal of Medicine;2/5/2004, Vol. 350 Issue 6, p552 

    Background: Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface proteins that protect the cells against attack by the complement system. We tested the...

  • A case of cranial venous sinus thrombosis and proteinuria. Agarwal, Vikas; Chauhan, S.; Singh, R. // Journal of Postgraduate Medicine;Apr-Jun2005, Vol. 51 Issue 2, p137 

    Presents a case of cranial venous sinus thrombosis and proteinuria in an 18-year-old male. History of dyspnoea on exertion, intermittent icterus, colicky abdominal pain and cola-colored urine; Thrombosis as a complication of paroxysmal nocturnal hemoglobinuria (PNH); Reason why red blood cells...

  • American Society of Hematology.  // BioWorld Today;12/8/2009, Vol. 20 Issue 235, p6 

    The article reports on the new data offered by Alexion Pharmaceuticals Inc. which showed that paroxysmal nocturnal hemoglobinuria (PNH) was improved by Soliris in patients with no history of prior blood transfusions. The new data revealed that those patients with PNH demonstrated increased...

  • Paroxysmal Nocturnal Hemoglobinuria in Children. van den Heuvel-Eibrink, Marry M // Pediatric Drugs;2007, Vol. 9 Issue 1, p11 

    Paroxysmal nocturnal hemoglobinuria (PNH), an acquired hematologic disorder characterized by intravascular hemolysis, nocturnal hemoglobinuria, thrombotic events, serious infections, and bone marrow failure, is very rare in children. PNH is caused by a somatic mutation of the...

  • Clinical: Paroxysmal nocturnal haemoglobinuria. Balasubramaniam, Thara; Kelly, Richard; Hill, Anita; Hillmen., Peter // GP: General Practitioner;11/18/2011, p35 

    The article offers information on Paroxysmal nocturnal hemoglobinuria (PNH). It states that PNH is a rare disease of bone marrow, in which produces blood cells which lack complement regulatory proteins, CD55 and CD59, making them susceptible to complement attack and hemolysis. Symptoms of PNH...

  • Eculizumab: A Guide to its Use in Paroxysmal Nocturnal Hemoglobinuria. Keating, Gillian M.; Lyseng-Williamson, Katherine A.; McKeage, Kate // BioDrugs;2012, Vol. 26 Issue 2, p125 

    The targeted terminal complement inhibitor eculizumab (Soliris®) reduces intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria (PNH), as well as stabilizing hemoglobin levels, improving fatigue and health-related quality of life, and reducing the requirement for packed...

  • Black Mornings, Yellow Sunsets – A Day with Paroxysmal Nocturnal Hemoglobinuria. Schwartz, Robert S. // New England Journal of Medicine;2/5/2004, Vol. 350 Issue 6, p537 

    The article presents an editorial looking at paroxysmal nocturnal hemoglobinuria (PNH). The attributes of PNH include complement-dependent intravascular hemolytic anemia, thrombosis, and bone marrow failure. Hemolysis typically occurs during sleep and the patient's urine is black in the morning...

  • Eculizumab.  // Reactions Weekly;Apr2014, Vol. 1497 Issue 1, p18 

    The article presents a case study of a 65-year-old female patient with wound sepsis which developed while receiving eculizumab for paroxysmal nocturnal haemoglobinuria (PNH) and with PNH flare that developed after eculizumab was discontinued.

  • Blue kidney in a pale patient—a case for a causal association between renal haemosiderosis in paroxysmal nocturnal haemoglobinuria and chronic kidney disease. Asim, Muhammad; Iqbal, Zafar; Mujeeb, Imaad Bin // Nephrology Dialysis Transplantation;Oct2009, Vol. 2 Issue 5, p365 

    A 50-year-old man presented with pancytopenia and chronic renal impairment. He had evidence of intravascular haemolysis. The direct antiglobulin (Coomb’s) test was negative. Paroxysmal nocturnal haemoglobinuria (PNH) was diagnosed by the Ham acid haemolysis test. There were no other...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics